Aktuell 10 mai 2024 BioVersys erweitert Serie-C-Runde auf 44,9 Millionen Franken BioVersys verstärkt die Zusammenarbeit mit GSK, um die Entwicklung von Alpibectir zur Behandlung von Tuberkulose zu beschleunigen. GSK beteiligt ...
News 17 abr 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
News 04 abr 2024 Galderma completes largest IPO on a global level in Q1 Galderma has banked nearly 2.3 billion Swiss francs following its listing on the SIX Swiss Exchange. The pharma firm was therefore responsible fo...
News 13 mar 2024 PSI developing new cancer therapy Researchers from the Paul Scherrer Institute (PSI) have developed a radiopharmaceutical to combat metastatic neuroendocrine tumors. After having ...
Aktuell 26 mar 2024 Zürcher Forschende machen Krebstherapie wieder wirksam Forschende der Universität Zürich und des Universitätsspitals Zürich haben herausgefunden, wie mutierte Blutkrebszellen wieder auf eine Immunther...
Aktuell 04 abr 2024 Galderma realisiert weltweit grössten Börsengang Die Kotierung an der Schweizer Börse hat Galderma knapp 2,3 Milliarden Franken eingebracht. Damit stellt das Pharmaunternehmen im ersten Quartal ...
Actualités 17 abr 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
News 19 dez 2023 Top Stories from Western Switzerland (October-December 2023) From achieving top rankings in global innovation to making significant advancements in healthcare and technology, discover Western Switzerland's ...
News 22 dez 2023 USZ now using tilbago debt collection software University Hospital Zurich (USZ) has replaced its previous SAP-based debt collection software solution with Robo-Inkasso from tilbago AG. Accordi...
Rapporti settoriali 23 jan 2024 Opportunità fintech internazionali per le aziende svizzere Questo rapporto completo del think tank svizzero e.Foresight fornisce alle PMI fintech svizzere le informazioni necessarie per orientarsi nel pan...
News 04 dez 2023 Siegfried, a Swiss leader taking innovations to industrial scale for the pharmaceutical industry From a small operation in Aargau to a global CDMO powerhouse, Siegfried's journey reflects strategic growth, innovation, and a deep commitment to...
News 03 nov 2023 EPFL and Novochizol to collaborate on designing more efficient immunotherapies A groundbreaking collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatm...
News 27 out 2023 UZH researchers develop method for transport of large genes Researchers at the University of Zurich (UZH) have developed a new method for transporting large genes, enabling them to be transferred efficient...
News 20 out 2023 Xlife Sciences becomes main shareholder in 4D Lifetec Xlife Sciences, a listed accelerator and investor in innovative healthcare solutions, has made an investment totalling 23.3 million Swiss francs ...
Actualités 29 fev 2024 Les Grands Titres de Suisse occidentale (Février 2024) D’importantes avancées en matière de semi-conducteurs et de percées dans la recherche médicale à des avancées stratégiques dans les secteurs de l...
News 10 out 2023 HES-SO Valais-Wallis and Debiopharm partner up to battle cancer HES-SO Valais-Wallis and Debiopharm have entered a partnership to advance targeted cancer therapy research with novel antibody conjugates.